Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
For adolescents and young adults with cancer, individualised care that addresses their unique medical and psychosocial needs is essential to improving outcomes and quality of life
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
Computational models can overcome current limitations of 3D analysis of tumour samples
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
For Prof. Brigette Ma, dealing with diversity and finding opportunities in criticisms are essential to grow as oncology professionals
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.